Is Semax more stable than most research peptides?

In enzymatic terms, yes — the proline content is there precisely for that. Chemically, its methionine still oxidises like any other.

Does Semax need a reducing agent?

No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.

Why swirl instead of shake?

Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence.

Semax (ACTH Fragment Peptide)

Semax Storage, Stability and Reconstitution

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Semax is supplied lyophilised and is most stable in that state, stored cold, dry and protected from light. Its proline content confers unusual resistance to enzymatic degradation and it contains no cysteine, so the main chemical liability is oxidation of its single methionine.

Key facts

Supplied as: White lyophilised powder
Main degradation route: Methionine oxidation (+16 Da)
Oxidation-prone residue: Met1 (one only)
Disulfide risk: None — no cysteine
Enzymatic resistance: High — two prolines
Lyophilised storage: Cold, dry, dark
Freeze-thaw: Avoid by aliquoting

Why the lyophilised form is the stable one

Freeze-drying removes water, and water participates in peptide-bond hydrolysis. A dry powder held cold has limited routes to degrade. This is general to research peptides rather than specific to Semax, and it is why the condition of material on arrival matters — a warm transit is time spent in a less protected state.

What makes Semax comparatively robust

Two features. Its proline content resists most peptidases, which is the property the Pro-Gly-Pro extension was added to provide. And at seven residues it is short, with correspondingly few bonds available to hydrolyse. Compared with a 39-residue lipidated peptide, this is a straightforward molecule to keep intact.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

The one real liability

Methionine at position 1. Its thioether sulfur oxidises to the sulfoxide in the presence of dissolved oxygen, accelerated by light and heat, adding 16 Da. This is the reason cold, dark, dry storage is specifically indicated rather than generically advised. With one methionine, a degraded sample shows a +16 satellite; a +32 peak would indicate something other than simple methionine oxidation and is worth investigating.

What does not apply

No cysteine means no disulfide formation, no scrambling and no reducing agent in buffers. That removes a whole category of handling complexity present for cysteine-containing peptides.

Reconstitution

Bacteriostatic water — sterile water preserved with 0.9% benzyl alcohol — is the usual diluent for research peptides, permitting repeated entry over a limited window. Introduce solvent gently against the vial wall rather than directing it onto the powder, and swirl rather than shake. Shaking creates an air-liquid interface at which peptides denature; foaming is the visible sign it has happened.

After reconstitution

Solution-phase material is subject to hydrolysis and oxidation, and stability falls accordingly. Aliquot into single-use volumes rather than freeze-thawing repeatedly — each cycle concentrates solutes at the advancing ice boundary and exposes the peptide to interfaces. Cloudiness, particulates or discolouration mean the material should not be relied on for a measurement.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Semax more stable than most research peptides?: In enzymatic terms, yes — the proline content is there precisely for that. Chemically, its methionine still oxidises like any other.
Does Semax need a reducing agent?: No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.
Why swirl instead of shake?: Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum